The U.S. pledges $1 billion for virus vaccine development

The company has the vote of confidence of the United States Government.

At the end of April, AstraZeneca joined forces with Oxford University to develop, produce and distribute the drug designed by the university, if successful. According to the university, the drug is currently in the human-trials, and they will have promising results by fall.  

The drug manufacturer has just been supported by the U.S. Government with $1 billion to speed up the developing process. By this agreement, the U.S.A should have 300 million doses of vaccine available. The first batch should be available for delivery in October. On top of that, AstraZeneca must conduct a Phase 3 trial in the States on 30,000 volunteers this summer. The funding is part of the "Operation Warp Speed" initiative. Through this program, the U.S. showed its support to Moderna, Sanofi, and Johnson & Johnson, in their efforts to find a vaccine against the novel virus. 

The U.K. will be the one who will have access to the vaccine and has already secured 30 million doses for September. Those will be the first out of 100 million. The company has been funded two times by the British government with 47 million pounds and another 84 million approved this past Sunday. 

AstraZeneca works on two fronts regarding the vaccine, as it has a 7.7% stake in biotech company Moderna, whose own vaccine showed promising results. Given the fact that Moderna’s stock has increased 275% this year, AstraZeneca’s market cap exceeds $2 billion.

Do you want to know what happened on the market lately? Register now and stay updated with Capex.com!

Sources: marketwatch.com, theguardian.com, edition.cnn.com


The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.